CPIX icon

Cumberland Pharmaceuticals

4.36 USD
+0.13
3.07%
At close Apr 1, 4:00 PM EDT
1 day
3.07%
5 days
1.40%
1 month
-15.18%
3 months
95.52%
6 months
246.03%
Year to date
95.52%
1 year
159.52%
5 years
23.16%
10 years
-37.27%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

9,800% more call options, than puts

Call options by funds: $297K | Put options by funds: $3K

67% more capital invested

Capital invested by funds: $2.61M [Q3] → $4.36M (+$1.75M) [Q4]

1.38% less ownership

Funds ownership: 14.5% [Q3] → 13.12% (-1.38%) [Q4]

9% less funds holding

Funds holding: 22 [Q3] → 20 (-2) [Q4]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

Research analyst outlook

We haven’t received any recent analyst ratings for CPIX.

Financial journalist opinion

Based on 3 articles about CPIX published over the past 30 days

Neutral
PRNewsWire
1 week ago
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas.
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Neutral
Seeking Alpha
4 weeks ago
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Fourth Quarter 2024 Financial Report and Company Update.
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
4 weeks ago
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval  NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period.
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Neutral
PRNewsWire
1 month ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
Neutral
PRNewsWire
1 month ago
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI , Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China.
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Positive
Benzinga
1 month ago
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
On Tuesday, Cumberland Pharmaceuticals Inc.  CPIX released topline results from its Phase 2 FIGHT DMD trial.
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
Neutral
PRNewsWire
1 month ago
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
NASHVILLE, Tenn. , Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial.
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Positive
Benzinga
3 months ago
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's  CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
Neutral
PRNewsWire
3 months ago
FDA APPROVES ACETADOTE® sNDA
-  New Dosing Regimen Simplifies Administration  - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product.
FDA APPROVES ACETADOTE® sNDA
Neutral
Seeking Alpha
4 months ago
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™